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1. Introduction 
Therapy by drugs that block the activity of the protein Bcr-Abl, specific inhibitors of Bcr-Abl 
tyrosine kinase (TKI), significantly changed the prognosis of chronic myeloid leukemia 
(CML). Bcr-Abl gene is located on the Philadelphia chromosome (Ph'-chromosome), 
resulting from t(9;22) translocation, plays a key role in the onset and progression of CML. To 
date, the standard in the treatment of CML patients is imatinib mesylate (Gleevec, "Novartis 
Pharma AG", Switzerland). In addition, TKI 2nd generation, nilotinib and dasatinib, which 
differ in activity and impact points, also show encouraging results as first-line therapy of 
CML. According to an international multicenter study of IRIS (after 60 months of imatinib 
therapy) is shown that a complete hematologic remission was achieved in 96% of 
patients, major cytogenetic response - at 92%, complete cytogenetic response - 86% [1]. 
Imatinib treatment is well tolerated; treatment withdrawal because of intolerance is noted 
only in 5% of patients [2, 3]. The most frequent side effects are edema (peripheral edema, 
pleural or pericardial effusion, ascites, and pulmonary edema), rapid increase of body 
weight (independently from peripheral edema), nausea, vomiting, myalgia, muscle cramps, 
diarrhea, skin rash [4, 5]. 
Respiratory side effects of imatinib are rare. The most frequent among them are cough (9—
22%), dyspnea (5—16%), flu-like syndrome (11,1%), upper respiratory tract infections 
(16,5%), pneumonia (1—10%) [4, 5]. Quite infrequent complications are pulmonary fibrosis 
and drug-induced pneumonitis [6]. 
We have some cases of such complications in available literature [7, 8, 9, 10, 11, 12]. Signs 
and symptoms of pneumonitis are similar: constitutional symptoms, malaise, low-grade 
fever, dyspnea (both exertional and at rest), cough, interstitial pulmonary infiltrates [13]. 
These symptoms are nonspecific and are often seen in other disorders. Rosado M.F. et al. 
have published one of the first case reports of imatinib-induced pneumonitis in 63 year-old 
woman with CML. At month 2 of imatinib treatment she has experienced dry cough and 
moderate exertional dyspnea. At 5th month of imatinib treatment both cough and dyspnea 
have worsened and hypoxemia was found (SaO2 88%). The diagnosis was confirmed by 
results of CT scan and bronchoscopy with transbronchial needle aspiration, excluding 
bacterial, viral and fungal etiology of pneumonitis [8]. J.Rajda et al. have described drug-
induced pneumonitis in 77 year-old woman with CML during first 4 weeks of imatinib 
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treatment. The progressive exertional dyspnea has led to nearly complete disability, where 
she could feel comfortable only at rest; later on a low-grade fever occurred. SaO2 was 85% 
[13]. In other patients the disease manifestations, diagnostic approach and treatment were 
quite similar. 
Although most cases of imatinib-induced pulmonary adverse events have been reported in 
patients with early chronic phase CML (from 0.2 to 1.3%). Dyspnea during imatinib therapy 
is most often related to fluid retention and pulmonary edema. Fluid retention may be due to 
prolonged platelet-derived growth factor inhibition by imatinib. Platelet-derived growth 
factor pathways are involved in the regulation of interstitial fluid homeostasis [16]. Imatinib 
pneumonitis develops in the period from 10 to 282 days (median time, 49 days) after 
treatment with imatinib (range, 200 to 600 mg daily). Dyspnea, hypoxemia and fever are 
usually seen. The chest CT scan shows diffuse or patchy ground-glass opacity, 
consolidation, or fine nodular opacity. The lung pathology may show interstitial 
pneumonitis and fibrosis, destruction of alveolar septa, lymphocytic alveolitis, plasma cell 
infiltrates, or type II pneumocyte hyperplasia. The resolution of pneumonitis after 
corticosteroid therapy has been reported. Ohnishi et al [16] reported that pneumonitis 
developed in 4 of 11 patients with a history of imatinib-induced pneumonitis after 
reexposure to imatinib [7, 13]. Diagnose lung disease caused by taking drugs is not always 
easy due to lack of specific clinical and morphological manifestations.  
2. Clinical observations 
In 2007—2008 in Hematology Research Center (Moscow, Russia) we have observed 
(including retrospective) in CML patients 4 cases of suspected imatinib-induced 
pneumonitis (Table 1). Three female and 1 male patients aged 13, 64, 66, and 40 
correspondingly have initial diagnosis of chronic phase CML high-risk group, according to 
Sokal. The CML duration before imatinib treatment was 24, 11, 2, and 2.5 months and 
imatinib treatment duration – 73, 48, 7, and 13 months correspondingly. Pneumonitis has 
occurred at months 2, 13, 47 and 48 of imatinib treatment. 
 
Patient Gender Age at 
diagnosis, 
yrs 
CML 
diagnosis
Start of 
imatinib
Date of 
pneumonitis
Imatinib 
termination
Imatinib 
treatment 
duration 
before 
pneumonitis, 
months 
Imatinib 
treatment 
duration, 
months 
#1 F 13 XI/99 XI/2001 XII/2005 IX/2008 47 73 
#2 F 64 XII/02 XI/2004 XI/2008 XI/2008 48 48 
#3 F 66 I/08 III/2008 V/2008 XI/2008 2 7 
#4 M 40 IX/06 XI/2008 III/2008 III/2008 13 13 
Table 1. Characteristics of drug-induced pneumonitis patients. 
Here are the case reports of our patients with imatinib-induced pneumonitis. In 2 patients it 
was revealed after a short, while in another two it was associated with prolonged imatinib 
treatment. In each case, describes the stages of diagnosis lung disease that emerged while 
taking imatinib (including retrospective), and treatment. 
The first case of drug-induced pneumonitis, a 20 year-old woman, admitted to our center in 
November, 2007. At age of 13 (in November 1999) the patient was diagnosed with chronic 
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phase of CML, high-risk group by Sokal on the basis of leukocytosis (WBC 286×109/L ) with 
prominent left shift of differential count with 15% blasts, hyperthrombocytosis 2279×109/L, 
spleen +8 cm below costal margin, liver +1 cm below costal margin. It should be 
noted that under the new WHO classification of 2008, the patient was in accelerated 
phase CML. The Ph'-chromosome was found in 100% metaphases. Within two years she was 
treated with combinations of low-doses ARA-C with hydroxyurea or alpha-interferon (IFN-
α), and ARA-C + doxorubicin (7+3). The only result was temporary hematological response 
without a cytogenetic one. Moreover, the treatment was complicated by avascular necrosis 
of femoral head. Spleen began to increase gradually, up to 10% of blasts and 
basophiles (25% or more) was determined in peripheral blood . Since November, 2001 she 
was taking imatinib (400 mg daily) with restoration of complete hematological response. 
Despite the absence of cytogenetic response the imatinib dosage was increased to 600 mg 
daily only at month 32 of treatment. Since December, 2005 (after 11 months at imatinib, 600 
mg qd) for another 11 months she also received treatment for suggested disseminated 
tuberculosis with infiltration and destruction, though it was not confirmed bacteriologically. 
At the same time the daily imatinib dosage was increased to 800 mg daily because of 
increasing platelet count (up to 1800×109/L). After that she became doing worse with 
prominent weakness and exertional dyspnea. She has undergone an additional evaluation at 
Institute of tuberculosis. The CT scan has found multiple confluent areas of alveolar 
consolidation. The revision of lung biopsy, performed during antituberculosis treatment, 
revealed mild lymphoid and histiocytic infiltration of bronchioles. She was supposed to 
have exogenic allergic alveolitis of unknown origin and treated with methylprednisolon (8 mg 
daily) since May, 2007 along with imatinib. Four months of such treatment has led to further 
deterioration. The development of pulmonary complications during prolonged high-dose 
imatinib treatment, ineffectiveness of both antituberculosis drugs and methylprednisolon 
has allowed suggesting imatinib-induced alveolitis. At September, 2007 imatinib treatment 
was stopped and the patient has lost hematological response (hyperthrombocytosis, 
elevating WBC count). 
At admission to our center she was complaining of weakness, palpitations, dyspnea at 
minimal exertion, episodes of chest pain, sense of epigastral pressure, fever (up to 38,5º) 
during last 1—2 months, productive cough, pruritis in legs. At physical examination there 
was only low-grade fever and pigmentation. The chest was deformed because of scoliosis. 
Lung margins were normal, respiratory rate — 18 breaths per minute, on auscultation the 
expiratory prolongation (predominantly left-sided) with basilar rales were heard. Heart rate 
was about 120 bpm, liver and spleen were not enlarged. 
The hematological and cytogenetic resistance to imatinib treatment along with suggested 
non-hematological toxicity (alveolitis) necessitated the additional evaluation and moving 
the patient to 2nd line TKIs. 
The CT scan revealed prominent diffuse bilateral interstitial lung infiltration with 
honeycomb appearance in upper and middle parts of lungs, along with the focus of lung 
consolidation in paravertebral part of right S10 without effusion (Figure 1). This was 
considered as non-specific interstitial pneumonia with supervening infection at right S10. 
The bronchoscopy data was normal. The study of bronchoalveolar lavage excluded bacterial 
overgrowth, PCR analysis has revealed the cytomegalovirus DNA (DNA-CMV). The lavage 
sediment contained 49% alveolar macrophages, 33% segmented neutrophils, 7% eosinophils, 
and 11% lymphocytes. 
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She has undergone the chemotherapy cycle (5+2) along with antibacterial and antiviral 
drugs; corticosteroids were stopped. The tachycardia (up to 150 bpm), probably due to 
steroid cardiomyopathy and febrile neutropenia episodes, necessitated the usage of beta-1 
blockers (atenolol). 
 
  
Fig. 1. A, B. Chest CT scan of patient #1 (A — middle, B — lower parts): non-specific 
interstitial pneumonia with supervened infection. 
The serial CT scan showed some regression of interstital pneumonia with retraction of 
alveolar infiltration area (against the withdrawal of imatinib). But the infiltrative focus in 
right lower lobe has enlarged and pleural involvement appeared. The serum galactomannan 
level was increased to 2,55 ng/ml (normal < 0,5 ng/ml), permitting to diagnose invasive 
aspergillosis. In addition, the repetitive lavage evaluation has revealed Enterococcus spp. 
growth and HSV-1,2 DNA. We have added antifungal drugs (Amphotericin-B) and 
modified both antibacterial and antiviral therapy. Thus, the patient noted 
the multiple pulmonary pathology, which complicates the course of the underlying disease. 
Therapy has improved the medical condition of the patient: the fever became sub febrile and 
only few rales could be heard. Since February, 2008 she started treatment with 2nd 
generation TKI, dasatinib. 
At control evaluation (December, 2008) the medical condition of patient was good and stable 
without any fever. Dasatinib therapy allowed achieving not only complete hematological, 
but also minor cytogenetic response. The control CT scan picture has shown major 
improvement with virtually complete regression of interstitial lung infiltration (Fig. 2). 
This case demonstrates the development of complex pulmonary disease: a retrospectively 
revealed imatinib-induced pneumonitis after prolonged therapy with imatinib mesylate. 
Rapid worsening at increased dose of imatinib prompted to reevaluate the previous 
diagnosis of tuberculosis and to stop imatinib because of suggested exogenic allergic 
alveolitis. After the resolution of supervened severe pleuropneumonia mixed etiology and 
lung aspergillosis we became able to start dasatinib treatment with stabilization and 
improvement of both lung pathology and CML response. 
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In patient #2, 64 year-old woman, CML chronic phase (high-risk group) was diagnosed in 
December, 2002. At that moment she was complaining of malaise. There was splenomegaly 
(+6 cm below costal margin), liver size was normal. The peripheral blood analysis presented 
hyperleukocytosis (117×109/L), moderate thrombocytosis (669×109/L), left shift of 
differential count. Bone marrow aspirate was hypercellular, karyological examination 
revealed Ph-chromosome in 100% metaphases. In December, 2002 — November, 2004 she 
was treated with IFN-α, but achieved only hematological response without cytogenetic one. 
The next 2 years she was receiving imatinib, 400 mg daily, but didn't achieve major 
cytogenetic response. Since January, 2007 its dose was increased to 600 mg daily. In August, 
2008 she was evaluated for dry cough and dyspnea. There were no rales, or prominent 
tachypnea (respiration rate 20 per minute) and X-ray didn't find any abnormalities, but 
persistent complaints have prompted to suspect an imatinib side effect. In November, 2008 
the TKI treatment was interrupted. 
 
 
Fig. 2. Control CT scan of patient #1. Nearly complete regression interstitial lung infiltration. 
The patient was reevaluated in specialized pulmonologic center. The auscultation revealed 
basilar crepitation with respiratory rate 22 per minute and SaO2 97%. Pulmonary function 
tests showed airflow obstruction (isolated decrease of expiratory flow in distant airways). 
Static lung volumes were normal and diffusion capacity was moderately decreased. The 
lung biopsy was not performed. The chest CT scan found interstitial abnormalities with 
“ground glass” appearance. This data allowed to suggesting drug-induced pneumonitis. 
An 8-week prednisolone therapy (25 mg daily) and imatinib interruption has led to 
significant improvement with resolution of both complaints and CT scan abnormalities. 
Taking into account the imatinib intolerance (non-hematological toxicity grade 3) and 
primary cytogenetic resistance, we decided to begin treatment with 2nd generation TKI, 
nilotinib, 800 mg daily. The nilotinib treatment duration has reached now 24 months. She 
has achieved a major cytogenetic response (14% bcr/abl-positive cells by FISH). The 
complaints are absent. 
The previous experience helped us to suspect the association of drug-induced pulmonitis 
with imatinib treatment. Prompt patient evaluation, interruption of imatinib, and quick 
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response to prednisolone allowed suggesting the development of such a rare complication. 
Notably, the response to nilotinib underlines the importance of early beginning of 2nd 
generation TKI treatment in case of primary cytogenetic resistance and imatinib intolerance. 
Patient #3, 66 year-old woman, was admitted to Hematological Research Center in June, 
2008. The diagnosis of high-risk chronic phase CML was established in January, 2008. At 
diagnosis peripheral blood analysis showed high WBC count (113×109/L) with left-shifted 
differential count (blasts — 1%, myelocytes — 11%, metamyelocytes — 6,5%, bands — 24%, 
segmented — 33,5%, basophils — 8%, eosinophils — 5%, platelets — 849×109/L, Hb 103 
g/L). Bone marrow smear showed granulocytic predominance with Ph-chromosome in 98% 
metaphases. The spleen was +5 cm below costal margin. She also suffered from arterial 
hypertension, treated with lisinopril. Two months after diagnosis (since 01.03.2008) she 
began receiving imatinib at standard dose of 400 mg qd. But 2 weeks later she began doing 
worse and malaise, low-grade fever and progressive dyspnea appeared. Lung auscultation 
revealed expiratory prolongation without rales. Hemodinamically she was stable. Chest X-
ray revealed diffuse interstitial process, confirmed later by CT scan. 
The CT scan (Fig. 3) shows diffuse increase of pulmonary vascularity with its deformation 
by infiltration of intralobular paraseptal interstitium. There were also symmetrical areas of 
decreased pneumatization with “ground glass” appearance, predominantly in central parts 
of both lungs. Pleural and pericardial effusions were absent. 
 
 
Fig. 3. Chest CT scan with signs of interstitial lung disease (patient #3). 
The clinical presentation and CT scan data permitted to suspect these abnormalities to be 
an imatinib-induced pneumonitis (non-hematological toxicity grade 2). Imatinib was 
discontinued (since 01.05.2008), and corticosteroids (methylprednisolone, 40 mg daily for 
20 days with gradual dose tapering) were started. This therapy has led to significant 
dyspnea improvement with normalization of temperature and auscultatory findings. CT 
scan showed the same “ground glass” focuses, but their intensity has decreased. The 
complete resolution of signs and symptoms with delayed resolution of radiological 
findings after imatinib discontinuation and corticosteroid treatment confirmed the 
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suggested association of pneumonitis with imatinib treatment. During the treatment 
interruption (40 days) she has lost the hematological response (WBC — 25×109/L, 
platelets — 742×109/L). The patient continued treatment with imatinib in decreased dose 
(300 mg daily) and hypotensive treatment with lisinopril. Two weeks later the 
hematological response restored. The control caryological examination after 3 months of 
treatment has confirmed a major cytogenetic response (25% Ph+ metaphases). But 2 weeks 
after the treatment was resumed the dyspnea had relapsed, while control CT scan 
revealed deterioration (marked increase in size and intensity of previously seen “ground 
glass” focuses of interstitial infiltration). The increased vascularity was still remaining, 
along with paraseptal and interlobular interstitial infiltration. These findings once more 
confirmed the association of pneumonitis with CML treatment. After the imatinib 
discontinuation she has undergone 16-day methylprednisolone therapy (40 mg daily with 
gradual tapering). The treatment was discontinued and the hematological response was 
lost again, necessitating the hydroxyurea treatment (3 g daily). 
During 6 months of imatinib treatment this patient achieved optimal response, but it was 
lost shortly after the treatment interruption (due to toxicity). The non-hematological toxicity 
(imatinib-induced pneumonitis grade 2), necessitated the treatment swapping to 2nd 
generation TKIs — nilotinib or dasatinib. 
Nilotinib (Tasigna, AMN107, Novartis Pharma AG) is a structural analogue of imatinib. As 
well as imatinib, it binds ABL-tyrosine kinase in inactive conformation, but is 25—30 times 
more potent in vitro and active against the majority of its mutated forms (except T315I). 
Notably it has no cross-resistance with imatinib. Dasatinib (Sprycel, BMS-354825, Bristol 
Myers Squibb) structurally differs from imatinib. It binds ABL-tyrosine kinase in active 
conformation and also inhibits SRC-kinases superfamily; by vitro activity it is 300 times 
more potent, than imatinib and is active against all known mutated forms, except T315I. 
However, dasatinib should be used cautiously in hypertensive patients. The coexistent 
arterial hypertension in our patient led us to prefer nilotinib. 
At the moment of nilotinib treatment Ph'-chromosome was found in 100% metaphases and 
hematological response was absent too. Now the nilotinib treatment duration is 24 months; 
she has achieved stable hematological, complete cytogenetic and major molecular response. 
The control CT scan revealed nearly complete resolution of interstitial lung infiltration and 
the lung vascularity merely returned to normal pattern. No treatment interruptions needed 
and the patient noted good drug tolerability. 
Concerning the last case (#4) of 40 year-old male we have only  a brief information. The 
diagnosis of chronic phase CML, high-risk group by Sokal was established in September, 
2006 (neutrophilic leukocytosis with left-shifted of differential count, hyperthrombocytosis 
up to 2400×109/L and Ph'-chromosome by karyological examination). Two months later he 
began successfully taking imatinib (400 mg daily) for a year without side effects. However, 
in February, 2008 (13th month of treatment) low-grade fever and exertional dyspnea 
occurred. The evaluation allowed excluding infections. The CT scan has revealed “ground 
glass” lung abnormalities, with increased and deformed lung vascularity. The patient 
refused from further evaluation and treatment in specialized center. 
This case report is not representative for imatinib-induced pneumonitis. But our goal is to 
attract attention of physicians to be aware of typical complaints of patients with this 
pathology and diagnose it earlier. 
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3. Discussion 
The above-mentioned rare disease belongs to a group of interstitial lung diseases, including 
now more than 150 entries. Despite the etiological differences, including the diseases of 
unknown origin, all of them involve lung interstitium and its vasculature. This feature 
underlies their clinical, radiological and pathological similarity. 
According to CTC, both interstitial pneumonia and pneumonitis have 5 grades of severity. 
Grade 1 is asymptomatic and is revealed only radiologically (X-ray, CT scan). Grade 2 is 
characterized by signs and symptoms, not interfering activities of daily living. Typical 
clinical presentation along with disturbances of gaseous exchange and activities of daily 
living indicates a grade 3 pneumonitis. Grade 4 is a life-threatening condition with a need 
for respiratory support, and death from pneumonitis is considered as 5 grade of toxicity 
[14]. 
The pathological examination typically reveals both inflammatory infiltrates and areas of 
fibrosis. Radiological findings can't be used for differential diagnosis, because they lack 
specificity and are not only shared within this group, but also could be seen in non-related 
diseases. The high-resolution CT scan is more specific and is most useful in serial 
examinations. Equally important in differential diagnosis are arterial blood gas 
examination and bronchoscopy with transbronchial biopsies (4—6 specimens) and 
lavage. The obtained material should undergo bacteriological, virological and 
immunological examination. 
The mechanism of interstitial lung diseases is complex and has a number of distinctive 
features. It is thought to be a result of immune complex-mediated reaction with the 
principal role of T cells and cytokines. The alteration of alveolocytes leads to acute alveolitis. 
If it doesn't resolve, the inflammation extends to interstitium and its capillaries, leading to 
pneumosclerosis, alveolar deformation and disturbances of lung diffusion capacity [15]. 
The treatment of drug-induced pneumonitis consists of avoidance of allergen (here — 
imatinib) and prednisolone, 1 mg/kg body weight daily, for 2—4 weeks. The dose is then 
tapered to minimal, sufficient for good results of pulmonary function tests. If contact with 
allergen is avoided there is no need for continuous corticosteroid treatment [15]. 
Drug-induced pneumonitis is a rare complication of imatinib treatment in CML patients. In 
two cases it has developed more than 2 year after the beginning of treatment, despite its 
good tolerance earlier. In other cases it was revealed at first months of therapy, when good 
compliance is especially needed for achieving of optimal response. Unfortunately, the 
complete evaluation (bronchoscopy with transbronchial biopsy and lavage, pulmonary 
function tests, arterial blood gas examination) was not done in all patients at the time of 
pneumonitis which is associated with the rare detection of such cases, and often the 
unwillingness of patients carrying invasive research methods. For example, bronchoscopy 
with transbronchial biopsy and lavage were performed only in patient #1, the study of 
blood gases and pulmonary function tests in patient #2. Patients 
receiving outpatient treatment are often reluctant to conduct invasive research methods. 
However, the problem of doctors in clinical practice is, in particular, in explaining the 
importance and need for a comprehensive survey of every obscure case. Its data could 
elucidate the mechanism of drug-induced pneumonitis development. All of our patients had 
serial CT scan examination (with the identification of the characteristic CT picture 
of “ground glass”), the association of interstitial lung disease with imatinib treatment is 
followed up, and the effectiveness of corticosteroids is estimated. 
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4. Conclusion 
These case reports illustrate the importance of search for signs of toxicity at different phases 
of treatment. Careful searching for adverse events of imatinib in CML patients and 
differential diagnosis with similar diseases allows prompt diagnosis and treatment of both 
frequent and rare side effects, including those not in onco- hematology specialist clinics, but 
also in clinical practice. Proper changing of treatment strategy can help to avoid frequent 
and prolonged interruptions of treatment due to toxicity and increase the efficacy of 
treatment, permitting to achieve optimal results. 
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